NEW YORK,
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development
and commercialization of medically important, novel pharmaceutical products
for the treatment of life-threatening diseases, including diabetes and cancer.
Keryx's lead compound under development is Sulonex(TM) (sulodexide oral
gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid
compound for the treatment of diabetic nephropathy, a life-threatening kidney
disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4
clinical program under a Special Protocol Assessment with the Food & Drug
Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron-
based compound that has the capacity to bind phosphate and form non-absorbable
complexes. Zerenex is currently in Phase 2 clinical development for the
treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients
with end-stage renal disease. Keryx is also developing clinical-stage oncology
compounds, including KRX-0401, a novel, first-in-class, oral anti-cancer agent
that modulates Akt, a protein in the body associated with tumor survival and
growth, and a number of other key signal transduction pathways, including the
JNK and MAPK pathways, which are pathways associated with programmed cell
death, cell growth, cell differentiation and cell survival. KRX-0401 is
currently in Phase 2 clinical development for multiple tumor types. Keryx also
has an active in-licensing and acquisition program designed to identify and
acquire additional drug candidates. Keryx is headquartered in
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.